Opexa Testing T-Cell Vaccine for MS
Posted on: Thursday, 17 May 2007, 15:04 CDT
U.S. firm Opexa Therapeutics said it has finished enrolling patients in a phase 2b study of its T-cell vaccine Tovaxin for multiple sclerosis.
The company said it has recruited 150 patients with clinically isolated syndrome or relapsing/remitting forms of MS.
The patients will receive treatment for 52 weeks, with investigators analyzing data on the first 75 subjects to reach six months evaluability later this year.
With this milestone achieved, we now look forward to reporting a descriptive analysis in the fourth quarter of 2007 and the full data results in the second half of 2008, said Opexa president and chief executive officer David McWilliams. I am convinced that the ability to rapidly enroll this study across 35 U.S. centers reflects the high level of interest by multiple sclerosis patients in new safe and effective treatments.
Opexa said that studies of the T-cell vaccine show that vaccinating MS patients with peripheral, blood-derived, autologous, myelin-peptide selected T-cells appears to elicit the appropriate immune response.
Source: United Press International
Related Articles
- Opexa Finishes Patient Enrollment in MS Trial
- Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis
- Opexa Presents Encouraging Arthritis Research
- Opexa Announces Encouraging Clinical Data on Novel T-Cell Vaccination Therapy for Rheumatoid Arthritis
- Opexa Achieves Midpoint in Patient Admissions in Phase IIb Trial of Tovaxin(TM) for Multiple Sclerosis
- Opexa Begins Dosing Patients in Phase IIb Trial of Tovaxin(TM) for Multiple Sclerosis
- Opexa Begins Dosing in Trial for Multiple Sclerosis
- Positive Results for Opexa in Ongoing MS Study
- Opexa Launches Phase 2b Trial of MS Drug
 |
 |
User Comments (0)
RSS Feeds